A Combinatorial Approach to Wound Healing for Protein, Gene and Cell Therapeutics

蛋白质、基因和细胞治疗的伤口愈合组合方法

基本信息

批准号：
7815960
负责人：
ANDREW BAIRD
金额：
$ 42.02万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2010-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7815960
关键词：
Agonist Bacteria Benchmarking Biological Assay Biotechnology Cancer Center Planning Grant Cells Communities Contracts Development Disease Employment Enzyme-Linked Immunosorbent Assay Funding Gene Proteins Genes Grant Hour Injury Laboratories Lead Licensing Luciferases Maps Measurable Measures Modeling Molecular Cloning Monoclonal Antibodies Mus Neuropeptides Occupations Outcome Parents Peptides Pharmaceutical Preparations Physiological Positioning Attribute Pre-Clinical Model Preclinical Drug Evaluation Private Sector Process Proteins Recombinants Recruitment Activity Reporter Research Research Project Grants Role Specificity Technology Technology Transfer Testing Therapeutic Time Transgenic Mice Wound Healing Zebrafish analog combinatorial commercialization drug candidate drug development drug discovery human disease knock-down novel diagnostics novel therapeutics parent grant parent project programs promoter receptor skills success technology development therapeutic development

项目摘要

DESCRIPTION (provided by applicant): We propose an 14 month, milestone-driven, benchmarked research plan that extends a parent P20 Center grant focusing on bio-therapeutics development. The research will initially be executed by 6 newly hired academic research and technical positions at UCSD. Sustained and new employment in drug discovery, drug screening and drug development will be developed by partnerships with the San Diego's local biotechnology community. Specifically we will: (1) express a newly discovered recombinant neuropeptide protein that we identified in the parent grant (P20 GM078421). Analogs will be synthesized to identify functional domains and test agonists and antagonists. (2) develop high specificity monoclonal antibodies and create a quantitative ELISA assay to measure its role in disease. (3) evaluate preclinical models of wound repair by creating models of gene knock down and conditional knock outs to (a) establish its physiological relevance, (b) serve as models for drug discovery and (c) assist in converting the drug candidate to a drug lead. (4) identify its receptor by molecular cloning to establish an assay for drug discovery. (5) map the promoter to create a luciferase reporter transgenic mouse. (6) transfer technology generated to the private sector for further development. Funding will build on the success of the parent project, extend its scope, bring new fundamental skills to the laboratory, accelerate the tempo of scientific research and allow for significant job creation (and retention) by enabling hiring of additional staff, increasing hours of current part-time staff, and contracting for additional needed skills. The funded program will create 6 new full time positions, enable us to sustain 2 ongoing current research positions and with a successful outcome, we anticipate would generate an additional 5-15 new jobs in drug development research positions by technology transfer to the private biotechnology sector. Relevance: This research project describes 5 milestone and bench-marked specific AIMs that will create, test and validate a new therapeutic for wound healing. It will immediately create 6 full time positions and, if successful, its 6th AIM will create 5-15 new jobs by technology transfer to the private sector.

描述（由申请人提供）：我们提出了一项为期 14 个月的、里程碑驱动的基准研究计划，该计划扩展了母公司 P20 中心的资助，重点关注生物疗法的开发。该研究最初将由加州大学圣地亚哥分校新聘用的 6 名学术研究和技术职位执行。通过与圣地亚哥当地生物技术界的合作，将在药物发现、药物筛选和药物开发方面创造持续的新就业机会。具体来说，我们将：（1）表达我们在亲本资助（P20 GM078421）中鉴定的新发现的重组神经肽蛋白。将合成类似物以鉴定功能域并测试激动剂和拮抗剂。 (2) 开发高特异性单克隆抗体并创建定量 ELISA 测定法来测量其在疾病中的作用。 (3) 通过创建基因敲除和条件敲除模型来评估伤口修复的临床前模型，以 (a) 建立其生理相关性，(b) 作为药物发现模型，以及 (c) 协助将候选药物转化为药物药物铅。 (4)通过分子克隆鉴定其受体，建立药物发现的测定方法。 (5)对启动子进行定位，创建荧光素酶报告基因转基因小鼠。 (6) 将产生的技术转让给私营部门以供进一步开发。资金将建立在母项目成功的基础上，扩大其范围，为实验室带来新的基本技能，加快科学研究的节奏，并通过雇用更多员工、增加现有工作时间来创造（和保留）大量就业机会。兼职人员，以及签订额外所需技能的合同。该资助计划将创造 6 个新的全职职位，使我们能够维持 2 个当前正在进行的研究职位，如果取得成功，我们预计将通过向私营生物技术部门转让技术，在药物开发研究职位上创造额外 5-15 个新职位。相关性：该研究项目描述了 5 个里程碑和基准特定 AIM，这些目标将创建、测试和验证伤口愈合的新疗法。它将立即创建 6 个全职职位，如果成功，其第六个 AIM 将通过向私营部门转让技术来创造 5-15 个新就业岗位。

项目成果

期刊论文数量（39）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Phosphodiesterase inhibition attenuates alterations to the tight junction proteins occludin and ZO-1 in immunostimulated Caco-2 intestinal monolayers.

磷酸二酯酶抑制可减弱免疫刺激的 Caco-2 肠道单层中紧密连接蛋白 occludin 和 ZO-1 的改变。

DOI：
10.1016/j.lfs.2008.10.007
发表时间：
2009-01-02
期刊：
Life sciences
影响因子：
6.1
作者：
Todd W. Costantini;J. Deree;W. Loomis;James G. Putnam;Sung;A. Baird;B. Eliceiri;V. Bansal;R. Coimbra
通讯作者：
R. Coimbra

Burn-induced gut barrier injury is attenuated by phosphodiesterase inhibition: effects on tight junction structural proteins.

磷酸二酯酶抑制可减轻烧伤引起的肠道屏障损伤：对紧密连接结构蛋白的影响。

DOI：
发表时间：
2009-04
期刊：
影响因子：
0
作者：
Costantini, Todd W;Loomis, William H;Putnam, James G;Drusinsky, Dana;Deree, Jessica;Choi, Sunghyuk;Wolf, Paul;Baird, Andrew;Eliceiri, Brian;Bansal, Vishal;Coimbra, Raul
通讯作者：
Coimbra, Raul

Non-invasive quantification of brain tumor-induced astrogliosis.

脑肿瘤引起的星形胶质细胞增生的无创定量。

DOI：
发表时间：
2011-01-19
期刊：
影响因子：
2.4
作者：
Lee, Jisook;Borboa, Alexandra K;Baird, Andrew;Eliceiri, Brian P
通讯作者：
Eliceiri, Brian P

Vagal stimulation modulates inflammation through a ghrelin mediated mechanism in traumatic brain injury.

迷走神经刺激通过生长素释放肽介导的机制调节创伤性脑损伤中的炎症。

DOI：
发表时间：
2012-02
期刊：
影响因子：
5.1
作者：
Bansal, Vishal;Ryu, Seok Yong;Lopez, Nicole;Allexan, Sarah;Krzyzaniak, Michael;Eliceiri, Brian;Baird, Andrew;Coimbra, Raul
通讯作者：
Coimbra, Raul

Basic fibroblast growth factor in an animal model of spontaneous mammary tumor progression.

自发性乳腺肿瘤进展动物模型中的碱性成纤维细胞生长因子。